Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s Why

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $21.67, but opened at $22.24. Nanobiotix shares last traded at $22.76, with a volume of 5,662 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on NBTX shares. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Nanobiotix presently has a consensus rating of “Hold” and an average target price of $11.00.

Nanobiotix Stock Up 5.0%

The business’s 50 day simple moving average is $20.98 and its 200 day simple moving average is $14.26.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. purchased a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.